Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020908

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 020908 describes VAGIFEM, which is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the VAGIFEM profile page.

The generic ingredient in VAGIFEM is estradiol. There are seventy-five drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the estradiol profile page.
Summary for 020908
Applicant:Novo Nordisk Inc
Formulation / Manufacturing:see details
Pharmacology for NDA: 020908
Mechanism of ActionEstrogen Receptor Agonists
Medical Subject Heading (MeSH) Categories for 020908
Suppliers and Packaging for NDA: 020908
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VAGIFEM estradiol TABLET;VAGINAL 020908 NDA Novo Nordisk 0169-5176 0169-5176-03 8 APPLICATOR in 1 CARTON (0169-5176-03) > 1 INSERT in 1 APPLICATOR
VAGIFEM estradiol TABLET;VAGINAL 020908 NDA Novo Nordisk 0169-5176 0169-5176-04 18 APPLICATOR in 1 CARTON (0169-5176-04) > 1 INSERT in 1 APPLICATOR
Paragraph IV (Patent) Challenges for 020908
Tradename Dosage Ingredient NDA Submissiondate
VAGIFEM TABLET;VAGINAL estradiol 020908 2013-01-02

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;VAGINALStrength25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Mar 26, 1999TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;VAGINALStrength10MCG
Approval Date:Nov 25, 2009TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Sep 17, 2022Product Flag?Substance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.